What was the overall market valuation of the biopharmaceuticals market in Germany in 2024?

The overall market valuation was $21.84 Billion in 2024. Read More

What is the projected market valuation for the biopharmaceuticals market in Germany by 2035?

The projected valuation for 2035 is $32.97 Billion. Read More

What is the expected CAGR for the biopharmaceuticals market in Germany during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 3.81%. Read More

Which product type segment had the highest valuation in 2024 within the biopharmaceuticals market in Germany?

The Monoclonal Antibodies segment had the highest valuation at $8.0 Billion in 2024. Read More

What is the projected valuation for the Recombinant Proteins segment by 2035?

The projected valuation for the Recombinant Proteins segment by 2035 is $7.5 Billion. Read More

Which application segment is expected to grow the most in the biopharmaceuticals market in Germany by 2035?

The Cardiovascular Diseases application segment is expected to grow to $11.0 Billion by 2035. Read More

What was the valuation of the Cellular Therapies segment in 2024?

The Cellular Therapies segment was valued at $4.84 Billion in 2024. Read More

Which end-use segment had the highest valuation in 2024?

The Pharmaceutical Companies end-use segment had the highest valuation at $8.84 Billion in 2024. Read More

What is the projected valuation for the Intravenous route of administration by 2035?

The projected valuation for the Intravenous route of administration by 2035 is $12.99 Billion. Read More

Who are the key players in the biopharmaceuticals market in Germany?

Key players include AbbVie, Amgen, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck & Co., Novartis, Roche, Sanofi, and Takeda Pharmaceutical. Read More

Germany Biopharmaceuticals Market

ID: MRFR/Pharma/49168-HCR

200 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Germany Biopharmaceuticals Market Research Report: Size, Share, Trend Analysis By Product Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cellular Therapies), By Applications (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By End-use (Hospitals, Biotechnology Companies, Pharmaceutical Companies), and By Route of Administration (Intravenous, Subcutaneous, Intramuscular) - Growth Outlook & Industry Forecast 2025 To 2035

Germany Biopharmaceuticals Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Product Type (USD Billion)
  1. 4.1.1 Monoclonal Antibodies
  2. 4.1.2 Recombinant Proteins
  3. 4.1.3 Vaccines
  4. 4.1.4 Cellular Therapies
2. 4.2 Construction, BY Application (USD Billion)
  1. 4.2.1 Oncology
  2. 4.2.2 Autoimmune Diseases
  3. 4.2.3 Infectious Diseases
  4. 4.2.4 Cardiovascular Diseases
3. 4.3 Construction, BY End-use (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Biotechnology Companies
  3. 4.3.3 Pharmaceutical Companies
4. 4.4 Construction, BY Route of Administration (USD Billion)
  1. 4.4.1 Intravenous
  2. 4.4.2 Subcutaneous
  3. 4.4.3 Intramuscular
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Amgen (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
  10. 5.2.10 Takeda Pharmaceutical (JP)
    1. 5.2.10.1 Financial Overview
    2. 5.2.10.2 Products Offered
    3. 5.2.10.3 Key Developments
    4. 5.2.10.4 SWOT Analysis
    5. 5.2.10.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY PRODUCT TYPE
3. 6.3 GERMANY MARKET ANALYSIS BY APPLICATION
4. 6.4 GERMANY MARKET ANALYSIS BY END-USE
5. 6.5 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY PRODUCT TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Billion)
16. 6.16 CONSTRUCTION, BY END-USE, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY END-USE, 2024 TO 2035 (USD Billion)
18. 6.18 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY END-USE, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Construction Market Segmentation

Construction By Product Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Recombinant Proteins
Vaccines
Cellular Therapies

Construction By Application (USD Billion, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases
Cardiovascular Diseases

Construction By End-use (USD Billion, 2025-2035)

Hospitals
Biotechnology Companies
Pharmaceutical Companies

Construction By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Intramuscular

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”